Current European licensing regulations give precedence to the interests of drug companies. Silvio Garattini and Vittorio Bertele9 suggest changes to ensure they meet the needs of patients and doctors
No takes yet. Share an insight, caveat, or question.
Garattini et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: